Literature DB >> 8678831

Anti-EBNA1/anti-EBNA2 ratio decreases significantly in patients with progression of HIV infection.

B Winkelspecht1, F Grässer, H W Pees, N Mueller-Lantzsch.   

Abstract

Reactivation of EBV infection is common in immunocompromised individuals. We determined specific antibodies to EBV-encoded nuclear antigens (EBNA)1 and 2 in 102 sera of HIV-infected individuals. Anti-EBNA1/anti-EBNA2 ratio (E1/E2) is less than 1 in chronic infection and exceeds 1 in healthy EBV-positive carriers. 52% of cases had E1/E2 < 1. E1/E2 decreased remarkably during the progression of HIV infection. Detectable HIV-Antigen, decline of CD4+ cell count and CD4+/CD8+ ratio were correlated with an increasing prevalence of E1/E2 below 1. We conclude that determination of E1/E2 is useful in immunocompromised patients.

Entities:  

Mesh：

Substances：

Year:  1996        PMID： 8678831     DOI： 10.1007/bf01718160

Source DB:  PubMed          Journal:  Arch Virol        ISSN： 0304-8608            Impact factor:   2.574


  19 in total

Review 1.  Acquired immunodeficiency syndrome-related lymphoma.

Authors:  A M Levine
Journal:  Blood       Date:  1992-07-01       Impact factor: 22.113

Review 2.  Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation.

Authors:  D W Hanto; G Frizzera; K J Gajl-Peczalska; R L Simmons
Journal:  Transplantation       Date:  1985-05       Impact factor: 4.939

3.  Herpesviruses as co-factors in AIDS.

Authors:  S D Holmberg; A R Gerber; J A Stewart; F K Lee; P M O'Malley; A J Nahmias
Journal:  Lancet       Date:  1988-09-24       Impact factor: 79.321

4.  Epstein-Barr virus in AIDS-related primary central nervous system lymphoma.

Authors:  E M MacMahon; J D Glass; S D Hayward; R B Mann; P S Becker; P Charache; J C McArthur; R F Ambinder
Journal:  Lancet       Date:  1991-10-19       Impact factor: 79.321

Review 5.  Malignant lymphoproliferative diseases induced by Epstein-Barr Virus in immunodeficient patients, including X-linked, cytogenetic, and familial syndromes.

Authors:  D T Purtilo
Journal:  Cancer Genet Cytogenet       Date:  1981-11

6.  Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection.

Authors:  W Henle; G Henle; J Andersson; I Ernberg; G Klein; C A Horwitz; G Marklund; L Rymo; C Wellinder; S E Straus
Journal:  Proc Natl Acad Sci U S A       Date:  1987-01       Impact factor: 11.205

7.  Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study.

Authors:  T Lehtinen; J Lumio; J Dillner; M Hakama; P Knekt; M Lehtinen; L Teppo; P Leinikki
Journal:  Cancer Causes Control       Date:  1993-05       Impact factor: 2.506

Review 8.  NIH conference. Epstein-Barr virus infections: biology, pathogenesis, and management.

Authors:  S E Straus; J I Cohen; G Tosato; J Meier
Journal:  Ann Intern Med       Date:  1993-01-01       Impact factor: 25.391

9.  Expression of Epstein-Barr virus nuclear antigen 1,2A and 2B in the baculovirus expression system: serological evaluation of human antibodies to these proteins.

Authors:  A Hille; K Klein; S Bäumler; F A Grässer; N Mueller-Lantzsch
Journal:  J Med Virol       Date:  1993-03       Impact factor: 2.327

10.  Epstein-Barr virus infection in HIV-positive patients.

Authors:  A Telenti; D E Uehlinger; F Marchesi; D Germann; R Malinverni; L Matter
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1993-08       Impact factor: 3.267
View more
  5 in total

Review 1.  Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years.

Authors:  Ralf D Hess
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

Review 2.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

3.  Antibody titers against EBNA1 and EBNA2 in relation to Hodgkin lymphoma and history of infectious mononucleosis.

Authors:  Nancy E Mueller; Evelyne T Lennette; Kathryn Dupnik; Brenda M Birmann
Journal:  Int J Cancer       Date:  2011-08-30       Impact factor: 7.396

4.  Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma.

Authors:  Lynn I Levin; Ellen T Chang; Richard F Ambinder; Evelyne T Lennette; Mark V Rubertone; Risa B Mann; Michael Borowitz; Edward G Weir; Susan L Abbondanzo; Nancy E Mueller
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

5.  Evaluation of four commercially available Epstein-Barr virus enzyme immunoassays with an immunofluorescence assay as the reference method.

Authors:  Barbara C Gärtner; Ralf D Hess; Dirk Bandt; Alexander Kruse; Axel Rethwilm; Klaus Roemer; Nikolaus Mueller-Lantzsch
Journal:  Clin Diagn Lab Immunol       Date:  2003-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.